Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 29,020 shares of the medical equipment provider’s stock, valued at approximately $517,000. Cambridge Investment Research Advisors Inc. owned approximately 0.08% of Lantheus as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of LNTH. Vanguard Group Inc. increased its holdings in shares of Lantheus by 87.5% in the 2nd quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after purchasing an additional 689,954 shares in the last quarter. Marshall Wace North America L.P. increased its holdings in shares of Lantheus by 1,214.5% in the 2nd quarter. Marshall Wace North America L.P. now owns 1,054,170 shares of the medical equipment provider’s stock worth $18,975,000 after purchasing an additional 973,977 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Lantheus by 12.6% in the 2nd quarter. Renaissance Technologies LLC now owns 691,000 shares of the medical equipment provider’s stock worth $12,196,000 after purchasing an additional 77,200 shares in the last quarter. State Street Corp increased its holdings in shares of Lantheus by 3,932.8% in the 2nd quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock worth $10,891,000 after purchasing an additional 601,714 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Lantheus by 79.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 524,540 shares of the medical equipment provider’s stock worth $9,258,000 after purchasing an additional 232,856 shares in the last quarter. 89.25% of the stock is owned by institutional investors.

LNTH has been the subject of a number of research analyst reports. Zacks Investment Research raised Lantheus from a “hold” rating to a “strong-buy” rating and set a $18.00 target price for the company in a report on Thursday, August 3rd. Credit Suisse Group raised their price target on Lantheus from $14.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC restated a “buy” rating and issued a $22.00 price target on shares of Lantheus in a research note on Thursday, October 12th. Wells Fargo & Company upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, November 2nd. Finally, BidaskClub downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 17th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $24.50.

Lantheus Holdings, Inc. (NASDAQ:LNTH) opened at $22.70 on Monday. The stock has a market capitalization of $851.39 and a price-to-earnings ratio of 20.27. Lantheus Holdings, Inc. has a 52 week low of $7.95 and a 52 week high of $24.10. The company has a quick ratio of 2.46, a current ratio of 2.96 and a debt-to-equity ratio of -3.41.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.04. The firm had revenue of $79.94 million for the quarter, compared to the consensus estimate of $77.18 million. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the business posted $0.15 EPS. research analysts predict that Lantheus Holdings, Inc. will post 1.05 earnings per share for the current year.

In other news, SVP Timothy G. Healey sold 11,314 shares of the firm’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $21.51, for a total value of $243,364.14. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Michael P. Duffy sold 20,000 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $16.45, for a total value of $329,000.00. Following the completion of the transaction, the insider now owns 184,218 shares in the company, valued at $3,030,386.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 553,472 shares of company stock worth $9,528,859. Company insiders own 2.30% of the company’s stock.

WARNING: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/cambridge-investment-research-advisors-inc-invests-517000-in-lantheus-holdings-inc-lnth-stock/1728458.html.

Lantheus Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.